Project Grant P01AI191610
Award Date
7/8/25
Completion Date
5/31/30
Dollars Obligated
$3.6M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This $128,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel chimeric antigen receptor (CAR) T cell therapies to eliminate HIV reservoirs in non-human primate models. The goal is to engineer a second-generation anti-PD-1 CAR T cell therapy that can more specifically and safely deplete the pool of HIV-infected T follicular helper (Tfh) cells, which...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $862,398 to the Fred Hutchinson Cancer Center in Seattle, WA over a 5-year period starting on August 1, 2025. The goal of this project is to develop novel chimeric antigen receptor (CAR) T-cell therapies that can selectively target and deplete the PD-1+ HIV/SIV reservoir in non-human primate models. The research aims to advance understanding of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on enhancing the persistence of CD4CAR T-cell therapies to treat HIV infection. The $186,408 award will support research to characterize and overcome the inhibitory effects of soluble HIV antigen on CD4CAR T-cell function, as well as strategies to extend the persistence of these therapeutic T cells using the IL15...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $486,057 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The 5-year grant, awarded on June 6, 2025, will support the development of a multipronged mRNA gene therapy approach to address HIV persistence and enable a potential cure. The proposed research aims...
This Cooperative Agreement award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an individualized HIV cure strategy targeting the antibody-resistant component of the HIV reservoir. The $3,568,644 award, effective from July 7, 2025 to May 31, 2030, will support research to: Characterize the antibody-resistant HIV reservoir to identify sequences of resistant reservoir...
This Project Grant award of $343,744 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a comprehensive strategy for an Investigational New Drug (IND) submission and clinical development of a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy to functionally cure HIV infection. The key products and services to be delivered include: 1) Formulating a strategic plan...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,648,086.00 to The Trustees of the University of Pennsylvania to conduct research on immune repertoire remodeling following B cell-targeted CAR T cell therapy for induction of renal allograft tolerance in non-human primates. The research aims to develop new therapeutics and introduce novel technologies,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $489,500 to The Children's Hospital of Philadelphia Research Institute to investigate the cellular identity of the intact HIV reservoir. The key objectives are to: 1) Test the hypothesis that CD4+ T cells with provirus in closed chromatin are transcriptionally distinct from cells with provirus in open chromatin, and 2)...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...